In a project co-funded by the Novo Nordisk Foundation Centre for Basic Metabolic Research, researchers from Yale University have reversed type 2 diabetes and fatty liver disease in rats
Up until now, the treatment of type 2 diabetes and closely associated conditions such as fatty liver disease has had only limited success.
However, with Danish funding, the researchers from Yale School of Medicine have now developed an agent that can reverse type 2 diabetes and fatty liver disease in rats.
The research team from Yale is headed by Gerald I. Shulman, who is also the International Scientific Director at The Novo Nordisk Foundation Centre for Basic Metabolic Research, University of Copenhagen, which has co-funded the Yale project. Their results have just been published in the scientific journal, Science.
Gerald I. Shulman and his team have achieved remarkable results based on an agent originally used for weight loss more than 70 years ago. The agent, DNP (2,4-dinitrophenol) was successfully diluted, reformulated and given orally to rats. And their future hope is that these positive results will also come to benefit humans.
“Based on these promising results, we now hope to be able to conduct further studies as well as clinical tests”, Gerald I. Shulman states.
You can read the article in Science here.
Scientific Director Gerald I. Shulman